Contineum Therapeutics, Inc. CTNM

US Pharmaceuticals

$10.36 ▲ +0.58% (+$0.06)

Open $10.11

Prev Close $10.30

Day Range $10.01 – $10.58

52W Range $6.73 – $17.79

Market Cap $404.44M

Beta 1.03

EPS (TTM) $-1.77

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2024-04-05
Shares Out.	37,620,000
Website	contineum-tx.com ↗
Phone	13026587581
Employees	51
Revenue	$0
Gross Profit	$0
Net Income	-$18.7M
Free Cash Flow	-$52.2M
Total Assets	$257.0M
Total Liabilities	$11.6M
Equity	$245.4M

About Contineum Therapeutics, Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Contineum Therapeutics, Inc. is a publicly traded company under the ticker symbol CTNM on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.